Multiple Myeloma

Researchers suggest prior treatments and follow-up duration may play a larger role.

Gwen Nichols, MD, discusses challenges associated with the limited access to CAR T therapy and the need to expand outpatient and community care for patients.

Breanne Peyton-Thomas, PharmD, BCOP, discusses her work as a pharmacist at Ochsner Health on the CAR T-cell therapy team.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Mary McGann, PharmD, BCOP, offers insights into CAR T-cell therapy and the crucial role of pharmacists in mitigating resistance.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Patients can face barriers to BCMA-targeted treatments.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

Kelsea Seago, PharmD, discusses the crucial role of pharmacists in managing chimeric antigen receptor (CAR) T-cell therapy resistance.

Dan Schrum discusses the integral role of pharmacy specialists in translating clinical trial results to clinical practice.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

Dan Schrum highlights the crucial role of lymphodepletion in enhancing the effectiveness of CAR T cell therapy.

CD38 density may indicate the efficacy of monoclonal antibody treatment in patients with multiple myeloma.

The decision is based on positive results from the PERSEUS trial.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

Increased levels of absolute lymphocyte count are associated with improved response to BCMA-targeted CAR T-cell therapy.

β2-microglobulin may be an effective indicator of coagulation dysfunction in patients with newly diagnosed multiple myeloma (NDMM).

IMROZ study data show Isa-VRd may be a new standard of care.

Radiotherapy may have applications beyond symptomatic relief when used in combination with immunotherapy.

Researchers identify significant proteins involved in the growth and survival of malignant multiple myeloma cells.

Omar Nadeem, MD, discusses positive outcomes associated with GPRC5D-targeted CAR T-cell therapy.

Chimeric antigen receptor (CAR) T-cell therapy can engineer T cells to target malignant cells in multiple myeloma.

The monotherapy is compared with the combination regimen of elotuzumab plus pomalidomide and dexamethasone in adult patients with relapsed or refractory multiple myeloma.

An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

Ryan Haumschild discusses the evolving treatment landscape for patients with multiple myeloma.

Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.

Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.

Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.